ACM
RDY icon

Accent Capital Management’s Dr. Reddy's Laboratories RDY Stock Holding History

Accent Capital Management’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,000
Closed -$14K – 372
2025
Q4 		$14K Buy
1,000
+125
+14% +$1.75K 0.01% 166
2025
Q3 		$12.2K Hold
875
– – 0.01% 188
2025
Q2 		$13.2K Hold
875
– – 0.01% 201
2025
Q1 		$11.5K Hold
875
– – 0.01% 186
2024
Q4 		$13.8K Buy
+875
New +$13.1K 0.01% 130

Other funds holding RDY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AIM
Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Accent Capital Management's RDY Position: Q1 2026 in Review

Accent Capital Management sold out of Dr. Reddy's Laboratories (RDY) in Q1 2026, closing a stake of 1,000 shares — an estimated $14K sold.

Accent Capital Management first reported a position in RDY in Q4 2024 and held it in 5 quarters. The position peaked at $14K in Q4 2025. 249 funds tracked by Wall St. Rank hold RDY as of Q1 2026.

  • Accent Capital Management reported no remaining Dr. Reddy's Laboratories position as of Q1 2026 after selling out during the quarter.
  • Accent Capital Management sold 1,000 Dr. Reddy's Laboratories shares in Q1 2026, an estimated $14K.
  • Accent Capital Management first reported a position in Dr. Reddy's Laboratories in Q4 2024 and held it in 5 quarters.
  • Accent Capital Management's Dr. Reddy's Laboratories position peaked at $14K in Q4 2025.
  • 249 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2026.

Based on Accent Capital Management's 13F filing for Q1 2026, filed 11 May 2026.